Sucampo Pharmaceuticals, a developer of proprietary drugs based on prostones, announced terms for its IPO Tuesday. The firm is offering 3.8 million shares, including 625K from insiders, at a price range of $14 to $16. Cowen & Company is the lead manager on the deal.
